Ambroxol … more than an expectorant The benefit of using ambroxol in chronic respiratory diseases?
More details
Hide details
Sanofi Greece, Kallithea, Athens, Greece
Intensive Care Unit, 1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Oncology unit, 3rd Department of Internal Medicine, University of Athens, Sotiria Hospital, Athens, Greece
2nd Respiratory Medicine Department, Attikon Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
1st Respiratory Medicine Department, Sotiria Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
Pneumon 2019;32(4):155–160
Chronic respiratory diseases comprise of chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases and bronchiectasis, amongst others. Most of these long-term diseases are not curable and cause an enormous economic burden. Mucoregulators such as ambroxol have been used for decades as a treatment for pulmonary diseases, in order to reduce the burden of the disease and improve quality of life by promoting mucus clearance. Effects of ambroxol include the increase of surfactant production, cytokine reduction and counteracting of oxidative stress in the lungs. Positive effects of ambroxol have been described in vitro and in clinical studies for COPD, chronic bronchitis as well as in acute respiratory infections. In addition, antiviral, antibacterial and antifungal properties have been demonstrated. Αmbroxol has a good safety profile. In this short review article, the current clinical knowledge on Ambroxol is summarized.
CB is an employee of Sanofi. RN, and BP have received payments for lectures from Sanofi Greece. KM, LS and BP have received payment for advisory boards from Sanofi Greece.
CB wrote the manuscript. RN, KM, LS and BP were involved in the data analysis or interpretation of the data and have critically revised the article. All authors have approved the final version of the manuscript. All authors are accountable for accuracy and integrity of the work.
Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
Hillas G, Nikolakopoulou S, Hussain S, Vassilakopoulos T. Antioxidants and mucolytics in COPD management: when (if ever) and in whom? Curr Drug Targets 2013;14:225-34.
Cerutti P, Kapanci Y. Effects of metabolite VI11 of bromhexine (Na 872) on type II epithelium of the lung. An experimental and morphological study with reference to surfactant secretion. Respiration 1979;37:241-51.
Elmer G, Kapanci Y. Effect of ambroxol on pneumocyte type II cell. A morphological and biochemical study. Curr Pvobl Clin Biochern 1985;13:47-55.
Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res 2008;13:557-62.
Cazan D, Klimek L, et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf 2018;17:1211-24.
Sousa R, Lakha DR, Brette S, Hitier S. A Randomized, DoubleBlind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ambroxol Hard-Boiled Lozenges in Patients with Acute Pharyngitis. Pulmonary Therapy 2019;5:201–11.
Malerba M, Ragnoli B. Ambroxol in the 21st century: Pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008;4:1119-29.
Olivieri D. Ambroxol for the prevention of chronic bronchitis exacerbations: Long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: A double-blind study versus placebo. Respiration 1987;51:42-51.
Matthys H, de Mey C, Carls C, Ryś A, Geib A, Wittig T. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo controlled parallel group clinical trial vs. cefuroxime and ambroxol. Arzneimittelforschung 2000; 50:700-11.
European Medicines Agency (EMA) (2016) European Commission final conclusion on the Ambroxol and bromhexine Article-31 referral - Annex II - Scientific conclusion.
Plomer M, de Zeeuw J. More than expectorant: New scientific data on ambroxol in the context of the treatment of bronchopulmonary diseases. MMW Fortschr Med 2017;159:22-33.
Zhi QM, Yang LT, Sun HC. Protective effect of ambroxol against paraquat-induced pulmonary fibrosis in rats. Intern Med 2011;50:1879-87.
Yakoot M, Salem A, Omar AM. Clinical efficacy of farcosolvin syrup (ambroxol-theophylline-guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis 2010;5:251-6.
Sushko VO. Optimization of chronic obstructive pulmonary disease treatment in clean-up workers of the Chornobyl NPP accident in the remote period after irradiation. Probl Radiac Med Radiobiol 2015;20:457-66.
Cegla UH. Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Prax Klin Pneumol 1988;42:715-21.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019.
Baraltini DF, Daniotti S, Pierfederici P, Grassi C. Prevention of chronic exacerbations with ambroxol (mucosolvan retard) – an open, long-term study in 5,635 patients. Respiration 1989;55:84-96.
Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind randomised, multicenter, placebo-controlled study (the AMETHIST trial). Pulm Pharmacol Ther 2004;17:27-34.
Poole PJ Black PN. Oral mucolytic drugs for exacerbations for chronic obstructive pulmonary diseases: systematic review BMJ 2001;322:1271-4.
BTS guideline 2019.
Nobata K. Ambroxol for the prevention of acute upper respiratory disease. Clin Exp Med 2006;6:79-83.
Yang F. Oxygen-driving and atomized mucosolvan inhalation combined with holistic nursing in the treatment of children severe bronchial pneumonia. Pak J Pharm Sci 2015; 28:1477-80.
Li F. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol 2008;57:1-7.
Lu Q. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int J Antimicrob Agents 2010;36:211-5.
Lee SH. A novel inhaled multi-pronged attack against respiratory bacteria. Eur J Pharm Sci 2015;70:37-44.
Cheng C. Ciprofloxacin plus erythromycin or ambroxol ameliorates endotracheal tube-associated Pseudomonas aeruginosa biofilms in a rat model. Pathol Res Pract 2015;211:982-8.
Lu Q. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model. Chemotherapy 2013;59:51-6.
Li F. Effect of ambroxol on pneumonia caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model. Chemotherapy 2011;57:173-80.
Zhang Y. Synergy of ambroxol with vancomycin in elimination of catheter-related Staphylococcus epidermidis biofilm in vitro and in vivo. J Infect Chemother 2015;21:808-15.
Chen F, YX Zhang, CQ Zhang. Effect of ambroxol on the concentration of cefotaxime in the bronchoalveolar lavage fluid of rats with pulmonary fibrosis. Exp Ther Med 2015;9:539-42.
Hafez MM. Activity of some mucolytics against bacterial adherence to mammalian cells. Appl Biochem Biotechnol 2009;158:97-112.
Pulcrano G. Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm. FEMS Yeast Res 2012; 12:430-8.
Rene HD. Effects of ambroxol on Candida albicans growth and biofilm formation. Mycoses 2014;57:228-32.
Yamaya M. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res 2014;37:520-9.
Ulas MM. Protective effect of ambroxol on pulmonary function after cardiopulmonary bypass. J Cardiovasc Pharmacol 2008;52:518-23.
Refai M. Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: A randomized trial. Eur J Cardiothorac Surg 2009;35:469-73.
Wang X. Perioperative Lung Protection Provided by High-Dose Ambroxol in Patients with Lung Cancer. Cell Biochem Biophys 2015;73:281-4.
Xia DH. The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. Med Oncol 2010;27:697-701.
Dreger H. Fast-track pulmonary conditioning before urgent cardiac surgery in patients with insufficiently treated chronic obstructive pulmonary disease. J Cardiovasc Surg 2011;52:587-91.
Li Q, Yao G, Zhu X. High-dose ambroxol reduces pulmonary complications in patients with acute cervical spinal cord injury after surgery. Neurocrit Care 2012;16:267-72.
Baranwal AK, Murthy AS, Singhi SC. High-dose oral ambroxol for early treatment of pulmonary acute respiratory distress syndrome: An exploratory, randomized, controlled pilot trial. J Trop Pediatr 2015;61:339-50.
Maegawa GH. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009;284:23502-16.
Ambrosi G. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurobiol Dis 2015;82:235-42.
Lukas J. Enzyme enhancers for the treatment of Fabry and Pompe disease. Mol Ther 2015;23:456-64.
Babajani G. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant beta-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant. Mol Genet Metab 2012;106:323-9.
Bendikov-Bar I. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis 2013;50:141-5.
Suzuki T. Correction: Expression of human gaucher disease gene GBA generates neurodevelopmental defects and ER stress in drosophila eye. PLoS ONE 2015;10:0135619.
Suzuki T. Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS ONE 2013;8:69147.
McNeill A. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137:1481-95.
Zimran A, Altarescu G, Elstein D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis 2013;50:134-7.
European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC). Revised assessment report: ambroxol and bromhexine containing medicinal products. 2015. [cited 2018 Sept 09]. Available from: WC500184106.pdf.
Ren YC, Wang L, He HB, et al. Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat. J Pharm Sci 2009;98:1797–803.
Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;7:CD001287.